Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) EVP Joseph Truitt sold 25,000 shares of the stock on the open market in a transaction dated Monday, August 25th. The shares were sold at an average price of $10.82, for a total value of $270,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on ACHN shares. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, August 21st. They now have a $10.00 price target on the stock, up previously from $4.00. Separately, analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, August 18th. They now have a $17.00 price target on the stock, up previously from $6.00. Finally, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Achillion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $9.50.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 9.00% on Tuesday, hitting $11.75. The stock had a trading volume of 20,176,328 shares. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $12.06. The stock has a 50-day moving average of $7.81 and a 200-day moving average of $4.95. The company’s market cap is $1.149 billion. Achillion Pharmaceuticals also saw some unusual options trading activity on Monday. Traders acquired 8,149 call options on the stock. This represents an increase of approximately 633% compared to the typical volume of 1,112 call options.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.